Skip Navigation LinksHome > June 2014 - Volume 21 - Issue 3 > Testosterone, aging and survival: biomarker or deficiency
Current Opinion in Endocrinology, Diabetes & Obesity:
doi: 10.1097/MED.0000000000000057
ANDROGENS: Edited by David Handelsman

Testosterone, aging and survival: biomarker or deficiency

Shores, Molly M.a,b; Matsumoto, Alvin M.c,d

Collapse Box

Abstract

Purpose of review

The purpose of this study is to review recent studies that examined the association of endogenous and exogenous testosterone and mortality in older men.

Recent findings

Over the past several years, there has been a steep rise in testosterone prescriptions. The increased use of testosterone occurred in the context of several studies that reported an association between low serum testosterone and increased cardiovascular events and mortality. In contrast, recent studies have reported an association between testosterone treatment and adverse events. A testosterone treatment trial of mobility-impaired elderly men with prevalent cardiovascular disease was stopped due to increased cardiovascular events in the T-treated men and a meta-analysis reported increased cardiovascular events in T-treated men. In two recent large observational studies, testosterone treatment was associated with an increased risk for serious adverse cardiovascular events.

Summary

Low testosterone is associated with mortality in multiple cohort studies; however, it is unclear if this is a causal association or due to low testosterone being a biomarker of poor health. Given recent reports of adverse outcomes associated with testosterone treatment, a conservative use of testosterone is warranted in men with cardiovascular disease who may be at greater risk for adverse outcomes.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.